The impact of early endoscopic lesions on the clinical course of patients following ileocolonic resection for crohn’s disease: A 5-year prospective cohort study

United European Gastroenterology Journal

Volumn 1, Issue 4, 2013, Pages 294-298

  Yamamoto, Takayuki ^a   Bamba, Takuya ^a   Umegae, Satoru ^a   Matsumoto, Koichi ^a  

^a MIE UNIVERSITY   (Japan)

Author keywords

Crohn s disease; Endoscopic lesions; Postoperative recurrence; Prophylactic medications; Resection

Indexed keywords

CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; MESALAZINE;

ADULT; ARTICLE; COHORT ANALYSIS; COLORECTAL CANCER; CROHN DISEASE; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE RISK; REMISSION;

EID: 85006210397     PISSN: 20506406     EISSN: 20506414     Source Type: Journal    
DOI: 10.1177/2050640613495197     Document Type: Article

References (10)

1. Lock MR, Farmer RG, Fazio VW, et al. Recurrence and reoperation for Crohn’s disease: the role of disease location in prognosis. N Engl J Med 1981; 304: 1586–1588.
2. Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn’s disease. Gastroenterology 1990; 99: 956–963.
3. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn’s disease activity index: National Cooperative Crohn’s Disease Study. Gastroenterology 1976; 70: 439–444.
4. Sipponen T, Kärkkä inen P, Savilahti E, et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn’s disease and histological findings. Aliment Pharmacol Ther 2008; 28: 1221–1229.
5. Jones J, Loftus Jr EV, Panaccione R, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn’s disease. Clin Gastroenterol Hepatol 2008; 6: 1218–1224.
6. Sipponen T, Björkesten CG, Färkkilä M, et al. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn’s disease treatment. Scand J Gastroenterol 2010; 45: 325–331.
7. D’Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 2218–2224.
8. Yamamoto T. Factors affecting recurrence after surgery for Crohn’s disease. World J Gastroenterol 2005; 11: 3971–3979.
9. Simillis C, Yamamoto T, Reese GE, et al. A metaanalysis comparing incidence of recurrence and indication for reoperation after surgery for perforating versus non-perforating Crohn’s disease. Am J Gastroenterol 2008; 103: 196–205.
10. Reese GE, Nanidis T, Borysiewicz C, et al. The effect of smoking after surgery for Crohn’s disease: a meta-analysis of observational studies. Int J Colorectal Dis 2008; 23: 1213–1221.